• Lu-PIN-1 Study two-thirds enrolled
• Study testing ability of Veyonda to boost effect of Novartis experimental drug
• Noxopharm to initiate LuPIN-2 study.
SYDNEY, January 14, 2019: Noxopharm (NOX:ASX) today releases an interview with Associate Professor Louise Emmett, the co-Principal Investigator of the LuPIN-1 Study being conducted at St Vincent’s Hospital, Sydney.
LuPIN-1 is being conducted in men with late-state prostate cancer and involves combination therapy of Veyonda and an experimental radiopharmaceutical drug, 177lutetium-PSMA-617 (Lu-PSMA), previously owned by Endocyte Inc but now owned by Novartis following that company’s recent US$2.1 billion acquisition of Endocyte Inc.
For further information please download PDF attached:
Download this document
